Phospho-Nanog (S285) Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-Phospho-Nanog (S285) antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityPhospho-Nanog (S285)
Clonepolyclonal
Host SpeciesRabbit
Reactive Specieshuman
Isotypen/a
Formatpeptide affinity purified
Size0.08 mL, 0.4 mL
Concentrationvial concentration: 0.5
ApplicationsDot Blot (DB), ELISA (EIA)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionThis Nanog Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding S285 of human Nanog. NANOG is a Ttranscription regulator involved in inner cell mass and embryonic stem (ES) cels proliferation and self-renewal. It imposes pluripotency on ES cells and prevents their differentiation towards extraembryonic endoderm and trophectoderm lineages. This protein blocks bone morphogenetic protein-induced mesoderm differentiation of ES cells by physically interacting with SMAD1 and interfering with the recruitment of coactivators to the active SMAD transcriptional complexes. NANOG acts as a transcriptional activator or repressor. It binds optimally to the DNA consens
Immunogenn/a
Other Names[Homeobox protein NANOG; Homeobox transcription factor Nanog; hNanog; NANOG]
Gene, Accession #[NANOG], Gene ID: 79923, NCBI: NP_079141.2, UniProt: Q9H9S0
Catalog #MBS9211180
Price$165, $370
Order / More InfoPhospho-Nanog (S285) Antibody from MYBIOSOURCE INC.
Product Specific ReferencesKochupurakkal,B.S., Biochem. Biophys. Res. Commun. 365 (4), 846-850 (2008) Freberg,C.T., Mol. Biol. Cell 18 (5), 1543-1553 (2007)
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.